Vetscan Imagyst Unveils New AI Masses Technology for Faster Cancer Detection in Veterinary Clinics

Zoetis Inc., the world’s leading animal health company, has today announced a new Vetscan Imagyst capability, AI Masses, which uses best-in-class AI to analyze potentially neoplastic cells in lymph node and subcutaneous lesions. This addition offers veterinary health teams the ability to make more informed treatment decisions, improve clinic efficiency, elevate pet owners’ experience and expand access to care for pets.

Vetscan Imagyst AI Masses gives veterinary professionals the opportunity to analyze lesions suggestive of cancer in-clinic and with a fast turnaround. The deep-learning AI technology, trained by expert human clinical pathologists, unlocks insights to enable individualized treatment outcomes earlier for more cases, at the point of care.

Part of Zoetis' comprehensive cytological portfolio and commitment to continuous innovation in animal health, the seventh Vetscan Imagyst capability complements the existing Digital Cytology application. As with other AI applications, AI Masses only requires a single round of sample preparation with access to an add-on expert review* from a network of board-certified specialists through Zoetis’ Virtual Laboratory – making it easy to use with minimal disruption to clinic workflow, empowering confident case management.

Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer at Zoetis said: “Waiting for results can be stressful for pet owners – even more so when it involves a cancer screening. Our research shows that up to 75% of pet owners find abnormal results highly stressful.1 AI Masses is yet another point-of-care capability to deliver results in-clinic, further exemplifies Zoetis’ purpose to advance care for animals, shortening anxious wait times to allow for faster care decisions that help provide the best possible outcome.”

In addition to Vetscan Imagyst AI Masses, the company’s new point-of-care hematology analyzer, Vetscan Opticell™ will also be showcased at the booth, where the diagnostic team will be on hand to answer questions. With this latest expansion, Vetscan Imagyst becomes the only commercially available veterinary diagnostic tool of its kind to offer seven unique testing applications: AI Masses, Digital Cytology, AI Urine Sediment, AI Fecal, AI Equine Fecal, AI Dermatology, and AI Blood Smear, in one compact tabletop design.

To view the full diagnostics portfolio, visit https://www.zoetisdiagnostics.com/us